secwatch.observer — SEC 8-K summary
======================================

Issuer:     Benitec Biopharma Inc. (BNTC)
CIK:        0001808898
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001193125-24-136730
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Benitec reports Q3 net loss $4.3M, positive OPMD data, $40M PIPE closed
-----------------------------------------------------------------------

- Net loss of $4.3M ($1.64 EPS) vs $4.4M ($2.67 EPS) in Q3 2023; revenue $0.
- Cash $14.1M at Mar 31; subsequent $40M oversubscribed PIPE closed Apr 22 extends runway through 2025.
- First OPMD subject showed clinically meaningful improvements in swallowing at 90 days post BB-301 dose; no SAEs.
- Second subject dosed safely; third expected June 2024; 23 subjects enrolled in natural history study.
- Additional interim safety/efficacy data expected H2 2024; Suvretta Capital led PIPE.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/0001193125-24-136730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808898/000119312524136730/d792227d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-136730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer